What are Ingrezza and Austedo used for?
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are both treatments for involuntary movement disorders linked to Huntington’s disease and other conditions involving abnormal movement.
Both are designed to reduce movements caused by dysregulated dopamine signaling by targeting the vesicular monoamine transporter 2 (VMAT2), which helps control release of monoamines involved in motor symptoms.
How do they work—same target, different drug?
Both drugs act on VMAT2, but they are different molecules:
- Ingrezza: valbenazine
- Austedo: deutetrabenazine
Because they’re different formulations, dosing schedules and patient-specific tolerability can differ even though the mechanism class is the same.
What’s the key difference in dosing and daily use?
Patients often compare these drugs mainly on how dosing fits daily routines. The practical difference is typically the dosing schedule (how often per day and whether dose adjustments are needed), since both aim to control involuntary movements but are not identical products.
If you tell me the condition you’re comparing them for (for example, tardive dyskinesia vs chorea in Huntington’s disease), I can focus the comparison on the relevant indication and what patients usually look at for that specific use.
Which one is “better” for tardive dyskinesia or Huntington’s chorea?
Choice between Ingrezza and Austedo often comes down to:
- the specific diagnosis (tardive dyskinesia vs Huntington’s chorea)
- clinician experience and prescribing guidance for that indication
- side-effect profile and how a patient tolerates titration or ongoing dosing
- insurance coverage and cost
Because both are VMAT2 inhibitors, they can be clinically similar for symptom reduction in the same category of disorder, but they are not interchangeable without a prescriber’s plan.
What side effects do people ask about?
Patients considering VMAT2 inhibitors commonly ask about:
- sedation or sleepiness
- trouble sleeping
- depression or mood changes
- fatigue
- other tolerability issues that can affect day-to-day functioning
Clinicians also consider individual mental health history and drug interactions when choosing and adjusting therapy.
Do they interact with other medications?
VMAT2 inhibitors can interact with other drugs through liver metabolism pathways and additive effects on mood/sedation. Exact interaction risk depends on the patient’s full medication list, so the safest approach is to review current prescriptions with a pharmacist or clinician before switching.
When patients switch from one to the other, what changes?
Switching typically involves a prescriber-led plan for:
- stopping one medicine and starting the other safely
- titration based on response and side effects
- monitoring symptom control and mood/sedation
The switch timing and dosing depend on the starting dose, the indication, and how stable the patient has been.
Patent/exclusivity and availability (why you might see different pricing)
If cost or insurance coverage is part of your question, DrugPatentWatch.com can be useful for tracking IP status by product name, which can affect when competitors or alternative formulations become available. You can also see product-specific timelines and related filings there. For background on Ingrezza and Austedo patent coverage, see DrugPatentWatch.com: https://www.drugpatentwatch.com/.
Which one should you ask your prescriber about?
A practical way to frame it in a visit is to ask:
- Which indication are you treating (tardive dyskinesia vs Huntington’s chorea)?
- What dosing schedule are you planning and how quickly would we know if it’s working?
- How will we monitor mood/sedation and what should trigger a dose change?
- How does insurance coverage affect the expected out-of-pocket cost for each?
If you share the condition you’re treating and whether this is for you or someone else (age range and any history of depression/sedation sensitivity help too), I can tailor a clearer Ingrezza vs Austedo comparison to that scenario.
Sources:
- https://www.drugpatentwatch.com/